Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Cellectis S.A.NASDAQ: CLLS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 21.5%

Gross margin was 21.5% in Q1 FY2026, down 59.6 pp from a year earlier. On a trailing-twelve-month basis it was 81.9%, up 0.5 pp year over year. Over 3 fiscal years it widened by 30.8 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
21.5%-49.7 pp QoQ
Last fiscal yearDec 2025
86.6%+8.7 pp YoY
LTMMar 2026
81.9%+0.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-59.6 pp——
1 year+8.7 pp——
3 years+30.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
86.6%
Year-over-year change
+8.7pp

Gross Margin vs competitors

How CLLS compares with its peers on the latest reported figures

  • CLLS's LTM Mar 2026 gross margin of 81.9% is the 2nd highest of the 6 companies compared; the peer median is 66.4%.
  • Its year-over-year change of +0.5 pp is the 2nd highest of 4, against a peer median of +0.0 pp.
  • Over three fiscal years its change of +30.8 pp compares with a peer median of +0.0 pp.
CLLS Competitors Peer median
Gross Margin for CLLS and competitors
Company Period LTM level YoY 3-year change
ACIUAC Immune S.A.LTM Mar 2026100.0% +0.0 pp+0.0 pp
CLLSCellectis S.A.LTM Mar 202681.9% +0.5 pp+30.8 pp
KRROKorro Bio, Inc.LTM Mar 202673.2% -26.8 pp—
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
AMRNAmarin Corporation plcLTM Mar 202652.5% +18.0 pp-9.1 pp
MREOMereo BioPharma Group plcLTM Mar 2026-105.7% ——
DRTSAlpha Tau Medical Ltd.FY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
DBVTDBV Technologies S.A.FY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding CLLS) 66.4%+0.0 pp+0.0 pp

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.